1. Kalra S, Baruah MP, Sahay RK, Unnikrishnan AG, Uppal S, Adetunji O. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. Indian Jurnal of Endocrinology and Metabolism 2016; 20(2):254-67. 2. Salcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders, British Journal of Pharmacology. 2012; 166: 1586–1599. 3. Akdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, Dhindsa S, Dandona P. Sitagliptin Exerts an Antinflammatory Action, Journal of Clinical Endocrinology and Metabolism, 2012; 97(9):3333–3341. 4. Bułdak Ł, Machnik G, Bułdak RJ, Łabuzek K, Bołdys A, Belowski D, Basiak M, Okopień B. Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner. Pharmacological Reports 2016; 68(2):329-37. 5. Dai Y, Dai D, Wang X, Ding Z, Mehta JL. DPP-4 Inhibitors Repress NLRP3 Inflammasome and Interleukin-1beta via GLP-1 Receptor in Macrophages Through Protein Kinase C Pathway, Cardiovascular Drugs and Therapy 2014; 28:425-32. 6. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4. Diabetes 2010; 59(4):1030-7. 7. Kappe C, Tracy LM, Patrone C, Iverfeldt K, Sjöholm Å. GLP-1 secretion by microglial cells and decreased CNS expression in obesity. Journal of Neuroinflammation 2012; 9:276. 8. Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, . Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 2011; 54(11):2745-54. 9. Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neuroscience Research 2006; 55(4):352-60. 10. Embleton M J. The Macrophage (2nd Edn). British Journal of Cancer 2003; 89(2): 421. 11. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Critical ReviewsTM in Eukaryotic Gene Expression 2010; 20(2):87-103. 12. Shiraishi D, Fujiwara Y, Komohara Y, Mizuta H, Takeya M. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochemical and Biophysical Research Communications 2012; 425(2):304-8. 13. Liu L, Wang Y, Fan Y, Li CL, Chang ZL. IFN-gamma activates cAMP/PKA/CREB signaling pathway in murine peritoneal macrophages. Journal of Interferon & Cytokine Research 2004;24(6):334-42. 14. Porcheray F, viaud s, rimaniol A-C, Leone C, Samah B, et al. Macrophage activation switching: an asset for the resolution of inflammation. Clinical & Experimental Immunology 2005; 142(3): 481–489. 15. Chang SY, Kim DB, Ryu GR, Ko SH, Jeong IK, Ahn YB, Jo YH, Kim MJ. Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway. Journal of Cellular Biochemistry 2013; 114(4):844-53. 16. Hibbs JB, Taintor RR, Varin Z, Rachilin EM. Nitric Oxide: acytotoxic activated macrophage, effect to molecule. Biochemical and Biophysical Research Communications 1989; 157:87-96. 17. Jorens Pj,Mattys Ke,Bult H. modulation of Nitric Oxide synthase activity in macrophage. Mediators of Inflammation 1995; 4:75-89. 18. Feng Y, Su L, Zhong X, Guohong W, Xiao H, Li Y, Xiu L. Exendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation. Journal of Molecular Endocrinology 2016; 56(3):189-99. 19. Xie X, Mo Z, Chen K, He H, Xie Y. Effect of glucagon like peptide-1 on proliferation and differentiation of endothelial progenitor cells and its mechanism. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010; 35(12):1254-60. 20. Liu L, Liu J, Huang Y. Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension. Journal of Cardiovascular Pharmacology 2015; 65(5):399-405. 21. Mittal J, Dogra N, Dass R, Majumdar S. In vitro effects of cAMP-elevating agents and glucocorticoid either alone or in combination on the production of nitric oxide, interleukin-12 and interleukin-10 in IFN-gamma- and LPS-activated mouse peritoneal macrophages. Folia Microbiologica 2002; 47(6):709-16. 22. Park YC, Park SJ, Jun CD, Kim GE, Park KI, Kim HD, Park RK, Chung HT. Cyclic AMP analogue as a triggering signal for the induction of nitric oxide synthesis in murine peritoneal macrophages. Cellular Immunology 1997; 179(1):41-7. 23. Sato S, Yanagawa Y, Hiraide S, Iizuka K. Cyclic AMP signaling enhances lipopolysaccharide sensitivity and interleukin-33 production in RAW264.7 macrophages. Microbiology and Immunology 2016; 60(6):382-9. 24. Aronoff DM, Canetti C, Serezani CH, Luo M, Peters-Golden M. Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. Jurnal of Immunology 2005; 174(2):595-9. 25. Tanaka M, Matsuo Y, Yamakage H, Masuda S, Terada Y, Muranaka K, et al. Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects. Metabolism 2016; 65(2):1-11. 26. Ma GF, Chen S, Yin L, Gao XD, Yao WB. Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-κB pathway. Acta Pharmacologica Sinica 2014; 35(2):195-202.